July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Is Trypan blue capsular staining really safe in cataract surgery?
Author Affiliations & Notes
  • Young Min Park
    Ophthalmology, Gyeongsang National University Changwon Hospital, Changwonsi, Gyeongsangnam-do, Korea (the Republic of)
  • Jong Moon Park
    Ophthalmology, Gyeongsang National University Changwon Hospital, Changwonsi, Gyeongsangnam-do, Korea (the Republic of)
  • Sung Who Park
    Pusan National University Hospital, Pusan, Korea (the Republic of)
  • Jong Soo Lee
    Pusan National University Hospital, Pusan, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Young Min Park, None; Jong Park, None; Sung Who Park, None; Jong Lee, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 432. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Young Min Park, Jong Moon Park, Sung Who Park, Jong Soo Lee; Is Trypan blue capsular staining really safe in cataract surgery?. Invest. Ophthalmol. Vis. Sci. 2018;59(9):432.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the safety of 0.03% trypan blue for staining the anterior capsule in cataract surgery.

Methods : The patients were classified into two groups. The trypan blue group comprised patients who had capsule staining with 0.03% trypan blue. The control group comprised patients who had capsulorhexis performed with an intracameral illuminator. The medical records of patients with vitreous hemorrhage who had pars plana vitrectomy and cataract surgery were reviewed. Preoperative and postoperative assessment included best corrected visual acuity, slit lamp examination, intraocular pressure, corneal endothelial status evaluated with specular microscopy at baseline, and at one and three months after surgery. The status of the endothelial cells in both groups was analyzed. Safety of 0.03% trypan blue on corneal endothelium was evaluated.

Results : Forty-five eyes were assigned to the trypan blue group and 41 eyes to the control group. Compared with the control group not showing significant endothelial cell density (ECD) changes postoperatively, the trypan blue group showed significant postoperative ECD loss at one month (7.91% loss, P < 0.001) and at three months (9.65% loss, P < 0.001). ECD did not decrease in 43.9% (18 eyes) of the control group, which was significantly greater than the 17.1% (7 eyes) of the trypan blue group. (P=0.004).

Conclusions : The ECD of the eyes decreased more with 0.03% trypan blue staining than those of the control group. Safety of trypan blue staining is not secured enough to abuse in all sort of cataract. Trypan blue should be used with caution, especially in patients with low preoperative ECD.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

Figure 1. A continuous curvilinear capsulorhexis performed using 0.03% trypan blue (A) and intracameral illuminator (B).

Figure 1. A continuous curvilinear capsulorhexis performed using 0.03% trypan blue (A) and intracameral illuminator (B).

 

Figure 2. Loss of the endothelial cell density at 3 months after surgery.

Figure 2. Loss of the endothelial cell density at 3 months after surgery.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×